Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 17:15:1395673.
doi: 10.3389/fphar.2024.1395673. eCollection 2024.

Current research update on group B streptococcal infection related to obstetrics and gynecology

Ying Liu  1 , Hao Ai  1
Affiliations
Review

Current research update on group B streptococcal infection related to obstetrics and gynecology

Ying Liu et al. Front Pharmacol. .

Abstract

Group B streptococcal (GBS) is a Gram-positive bacterium that is commonly found in the gastrointestinal tract and urogenital tract. GBS infestation during pregnancy is a significant contributor to maternal and neonatal morbidity and mortality globally. This article aims to discuss the infectious diseases caused by GBS in the field of obstetrics and gynecology, as well as the challenges associated with the detection, treatment, and prevention of GBS.

Keywords: antibiotic prophylaxis; group B streptococcal; group B streptococcal vaccine; microbial therapy; obstetrics and gynecology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Summary of GBS virulence factors elucidated in this review, with their mechanisms.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Absalon J., Segall N., Block S. L., Center K. J., Scully I. L., Giardina P. C., et al. (2021). Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect. Dis. 21 (2), 263–274. 10.1016/S1473-3099(20)30478-3 - DOI - PMC - PubMed
    1. Absalon J., Simon R., Radley D., Giardina P. C., Koury K., Jansen K. U., et al. (2022). Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. Hum. vaccines Immunother. 18 (1), 2037350. 10.1080/21645515.2022.2037350 - DOI - PMC - PubMed
    1. Aceil J., Paschall A. V., Knoot C. J., Robinson L. S., Scott N. E., Feldman M. F., et al. (2022). Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine. Vaccine 40 (42), 6107–6113. 10.1016/j.vaccine.2022.09.018 - DOI - PMC - PubMed
    1. Achten N. B., Dorigo-Zetsma J. W., van Rossum A. M. C., Oostenbrink R., Plötz F. B. (2020). Risk-based maternal group B Streptococcus screening strategy is compatible with the implementation of neonatal early-onset sepsis calculator. Clin. Exp. Pediatr. 63 (10), 406–410. 10.3345/cep.2020.00094 - DOI - PMC - PubMed
    1. ACOG committee opinion (1996). ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173--June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. Int. J. Gynaecol. obstetrics official organ Int. Fed. Gynaecol. Obstetrics 54 (2), 197–205. 10.1016/S0020-7292(96)90083-1 - DOI - PubMed

LinkOut - more resources